Concepedia

Author

Kristen Hege

Dana-Farber Cancer InstituteORCID

Also Known As

Hege K, Jinichi Mori, K Hege, K M Hege, K. Hege, Kristen Hege, Kristen M Hege, Kristen M. Hege

163

Publications

11.6K

Citations

44

H-Index

41

Concepts

All Affiliations

Dana-Farber Cancer InstituteSarah CannonBristol-Myers Squibb (United States)University of California, San FranciscoMassachusetts General Hospital
KH

About

Kristen Hege is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

16

1.4K

2

Immunology

11

13

1.3K

3

Health Sciences

3

3

267

4

Cell Biology

2

2

71

5

Cellular Therapies

1

1

15

Kristen Hege

×

67

Publications

10.8K

Citations

41

H-Index

YearCitations

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi, Larry D. Anderson, Nina Shah,

New England Journal of Medicine

2021

2.3K

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Noopur Raje, Jesús G. Berdeja, Yi Lin,

New England Journal of Medicine

2019

1.7K

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

John Scholler, Troy Brady, Gwendolyn Binder-Scholl,

Science Translational Medicine

2012

640

Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus–infected subjects

Ronald T. Mitsuyasu, Peter A. Anton, Steven G. Deeks,

Blood

2000

404

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

Mehmet Samur, Mariateresa Fulciniti, Anıl Aktaş Samur,

Nature Communications

2021

388

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

Alfons JM van den Eertwegh, Jurjen Versluis, H. Pieter van den Berg,

The Lancet Oncology

2012

356

Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

Dan Laheru, Eric R. Lutz, James M. Burke,

Clinical Cancer Research

2008

343

A Phase II Randomized Study of HIV-Specific T-Cell Gene Therapy in Subjects with Undetectable Plasma Viremia on Combination Antiretroviral Therapy

Steven G. Deeks, Bridget K. Wagner, Peter A. Anton,

Molecular Therapy

2002

315

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

Matteo Da Vià, Oliver Dietrich, Marietta Truger,

Nature Medicine

2021

314

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

Kristen Hege, Emily K. Bergsland, George A. Fisher,

Journal for ImmunoTherapy of Cancer

2017

312

Page 1